Great question! BiTE therapy (Bispecific T-cell Engagers) is an exciting newer treatment option for myeloma, particularly for relapsed or refractory multiple myeloma (RRMM) — meaning myeloma that has come back or stopped responding to other treatments.
Think of BiTEs as tiny bridges that connect your immune system's T Show Full Answer
Great question! BiTE therapy (Bispecific T-cell Engagers) is an exciting newer treatment option for myeloma, particularly for relapsed or refractory multiple myeloma (RRMM) — meaning myeloma that has come back or stopped responding to other treatments.
Think of BiTEs as tiny bridges that connect your immune system's T cells directly to myeloma cells, making it easier for your body to destroy them. There are currently four FDA-approved BiTE drugs:
- Teclistamab (Tecvayli) – approved 2022
- Elranatamab (Elrexfio) – approved 2023
- Talquetamab (Talvey) – approved 2023
- Linvoseltamab (Lynozyfic) – approved 2025
The first three target a protein called BCMA on myeloma cells. Talquetamab targets a different protein called GPRC5D. BiTEs are given as injections under the skin, usually in the stomach or thigh. Doses are gradually increased over the first couple of weeks, then given every one to four weeks. Like all treatments, BiTEs can cause side effects. Common ones include:
- Cytokine release syndrome (an immune overreaction ranging from mild flu-like symptoms to severe)
- Low blood cell counts
- Fatigue
- Fever
- Infections
- Nausea
- Headache
Talquetamab specifically may also cause nail changes, altered taste, dry mouth, and weight loss.
Always discuss the risks and benefits with your myeloma specialist to see if BiTE therapy might be right for you.
July 4
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
